MediWound Announces Presentation on EscharEx at the Advanced Wound Care Summit in Boston on July 13GlobeNewsWire • 07/08/22
MediWound Announces Positive Results from its U.S. Phase 2 Pharmacology Study of EscharEx for Debridement of Lower Leg UlcersGlobeNewsWire • 07/07/22
MediWound Ltd. (MDWD) CEO Sharon Malka on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/17/22
MediWound Announces Positive Results from Its U.S. Phase 2 Trial of EscharEx for Debridement of Chronic WoundsGlobeNewsWire • 05/12/22
MediWound to Report First Quarter Financial Results and Host a Conference Call and Webcast on May 17, 2022GlobeNewsWire • 05/10/22
MediWound's EscharEx Highlighted in Poster and Oral Presentation at the Symposium on Advanced Wound Care (SAWC) Spring 2022GlobeNewsWire • 04/12/22
MediWound to Present EscharEx Clinical Data at the Symposium on Advanced Wound Care (SAWC) Spring 2022GlobeNewsWire • 03/29/22
MediWound Announces Last Patient Out in EscharEx U.S. Phase 2 Trial for the Debridement of Chronic WoundsGlobeNewsWire • 03/21/22
MediWound Ltd. (MDWD) CEO Sharon Malka on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/17/22
MediWound to Report Fourth Quarter and Year End 2021 Financial Results and Host a Conference Call and Webcast on March 17, 2022GlobeNewsWire • 03/10/22
MediWound (MDWD) Could Find Support Soon, Here's Why You Should Buy the Stock NowZacks Investment Research • 03/09/22
Earnings Preview: MediWound (MDWD) Q4 Earnings Expected to DeclineZacks Investment Research • 02/17/22
MediWound Awarded a U.S. Department of Defense Research Grant for the Development of NexoBrid for the U.S. ArmyGlobeNewsWire • 02/17/22